Programmed Cell Death, Type II
Showing 1 - 25 of >10,000
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell
Recruiting
- Primary Immune Deficiency
-
Bethesda, Maryland
- +6 more
Feb 2, 2023
Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)
Not yet recruiting
- Acute Lymphoblastic Leukemia in Pediatric
- flow cytometric immunophynotyping
-
Sohag, EgyptSohag University Hospital
Jun 19, 2022
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,
Not yet recruiting
- Muscle-Invasive Bladder Carcinoma
- +2 more
- Toripalimab
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Aug 3, 2023
PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Monza, ItalyASST-Monza Ospedale San Gerardo
Jun 9, 2022
Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Atezolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 15, 2022
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Tumor-Infiltrating Lymphocytes and Programmed Cell Death -
Recruiting
- Breast Cancer
- +2 more
- Observational Study
-
Lucknow, Uttar Pradesh, IndiaSanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in
Recruiting
- Malignant Pleural Mesothelioma, Advanced
- Oncolytic Adenovirus H101
- Programmed death receptor-1 inhibitor
-
Tianjin, Tianjin, ChinaTianjin Medical Unversity Second Hospital
Sep 2, 2023
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib
Enrolling by invitation
- Hepatocellular Carcinoma Non-resectable
- +3 more
- lenvatinib + sindilimab/carrelizumab
- TACE
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
May 23, 2022
Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)
Active, not recruiting
- Metastatic Nonsmall Cell Lung Cancer
- Non Small Cell Lung Cancer
- Stereotactic Body Radiotherapy
-
Philadelphia, PennsylvaniaPhiladelphia CyberKnife
Mar 15, 2022
Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and
Recruiting
- Head and Neck Cancer
-
Strasbourg, FranceInstitut de cancérologie Strasbourg Europe
Apr 14, 2022
Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)
Withdrawn
- Malignant Melanoma
- tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
- (no location specified)
Nov 12, 2021
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)
Recruiting
- Relapsed Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Nivolumab
- Pembrolizumab
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023
Locally Advanced Basal Cell Carcinoma Trial in Philadelphia (biological, procedure, other)
Not yet recruiting
- Locally Advanced Basal Cell Carcinoma
- Cemiplimab
- +3 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jun 28, 2023
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023
Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)
Terminated
- Hodgkin's Lymphoma
- Pembrolizumab
- Umbralisib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 22, 2022